Swifsul 0,5 mg / 0,4 mg, Hard gelatine capsules.
PDF Leaflet Revision Date: 08 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
Dosage (summary)
One capsule orally after the same meal each day.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in women; may affect male fetal development.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP2D6 inhibitors
- PDE5 inhibitors
Contraindications
- Hypersensitivity to components
- Women and children
- Severe hepatic impairment
Common side effects
- Dizziness
- Impotence
- Altered libido
- Orthostatic hypotension
Counselling Points
- Avoid contact with leaking capsules
- Monitor for breast changes
- Report dizziness or weakness
Serious warnings
- Risk of prostate cancer
- Intraoperative Floppy Iris Syndrome
- Cardiac failure risk
Important Disclaimer
The Swifsul 0,5 mg / 0,4 mg, Hard gelatine capsules. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
